Few firms benefit from rewards under EU Paediatric Regulation
This article was originally published in Scrip
Executive Summary
Only a few companies have benefited from incentives for developing medicines for children since the European Paediatric Regulation came into force three years ago, says the European Medicines Agency in its first mandatory report on the regulation.